|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently, Estrogen Receptor beta (ERβ) has been found to be expressed in a fraction of TNBCs where, due to its oncosuppressive actions on the genome, it represents a potential therapeutic target, provided a better understanding of its actions in these tumors becomes available.
|
31792072 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study we examined whether expression of ERβ in turn might be affected by tumor suppressor PTEN, analyzed the effect of this interaction on tamoxifen response and the co-expression of both genes in human breast cancer samples.
|
31604073 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The shERβ + DAPT group reversed the effect of shERβ on the volume and weight of transplanted tumors.
|
31695429 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data clearly support the putative role of ERβ as tumor suppressor in endometrium as previously suggested in studies on other tissues and encourage further studies to find out to what extent this molecule might be a potential therapy target in this cancer entity.
|
31357971 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In two androgen receptor (AR)-positive prostate cancer cell lines, C4-2B and LNCaP, we first validated ERβ's tumor suppressor activity indicated by the inhibition of cell proliferation and repression of MYC expression.
|
30979864 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Estrogen receptor beta (ERβ) is a tumor suppressor gene in PCa.
|
29322786 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, we found that patients with tumor stage I-II showed higher ERβ mRNA expression levels and decreased expression of ERβ protein with increasing tumor grade, which is opposite to MDR1 expression.
|
31288527 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies suggest that estrogen receptor beta (ERβ), may function as a tumor suppressor in GBM.
|
30992459 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Of note, ERβ protein expression was significantly correlated with tumor size (P=0.018), lymph node metastasis (P=0.041), clinical stage (P=0.041) and differentiation (P<0.001).
|
30864727 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the levels of p-FOXO1 and estrogen receptor-β expression were significantly (P<0.05) correlated in UUTUC samples [correlation coefficient (CC)=0.244], particularly in tumor samples from male patients (CC=0.330).
|
30655790 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Triple-negative BCs showed low nuclear ER-β expression in 57.7%, and pCR rates were 27.1% and 0% (p = 0.23) in low and high ER-β expressing tumours, respectively.
|
31656321 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, we observed a higher expression of estrogen receptor beta in these tumors.
|
30738018 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, high ERα expression was associated with lower tumor differentiation in ESCC (OR = 1.64; 95% CI = 1.02-2.64, P = .04) and ERβ was linked with better tumor differentiation in gastric adenocarcinoma (GCA) (OR = 0.49; 95% CI = 0.26-0.94, P = .03).
|
31725654 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ERβ expression was lower in tumor tissue than in adjacent normal tissue of patients with breast cancer, and low levels of mitochondrial ERβ (mitoERβ) also were associated with increased tumor recurrence after surgery.
|
30873822 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ERβ isoform status and their unique interactions with oncogenic pathways may have important implications in GBM progression.<b>Significance:</b> These findings suggest that only ERβ isoform 1 has tumor suppressor function in GBM and that ERβ isoform switching contributes to GBM progression.<i></i>.
|
29661831 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both tumor subtypes showed similar levels of ERβ and GPER expression, although significant differences in ERβ and GPER expression were not detected.
|
29303935 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The resultant excess estrogen is inducing an overexpression of estrogen receptors (ERα and ERβ), harming tissues, leading to autoimmune diseases, and neoplasms.
|
29573619 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall survival of patients with tumors expressing cytoplasmic ERβ was significant longer compared to those with ERβ-negative ovarian cancer (chi-square statistic of the log-rank, p < 0.05).
|
30326857 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nuclear receptor estrogen receptor 2 (ESR2, ERβ) modulates cancer cell proliferation and tumor growth, exerting an oncosuppressive role in breast cancer (BC).
|
29509190 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Estrogen receptor beta (ERβ), a well-characterized tumor suppressor, is expressed in 30% of TNBCs, and its expression is associated with improved patient outcomes.
|
30257941 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A low proportion of EAC tumors stained positive for ERα (4%) and AR (3%) while approximately one third stained positive for ERβ (31%).
|
30450159 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Upregulation of ERβ and treatment with ERβ agonists potentiates the tumor suppressor function of p53 resulting in decreased survival.
|
29854295 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The partial loss of the ERβ in HGPIN indicates that the ERβ acts as a tumor suppressor.
|
29094395 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, a xenograft mouse model was used to observe differences in ERβ subtype tumor growth with respect to IL6 expression.
|
29970138 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ERβ up-regulated miR-92a could decrease DAB2IP tumor suppressor expression via binding to the miR-92a binding site located on the DAB2IP 3' UTR.
|
30459405 |
2018 |